retatrutide mechanism triple agonist glp-1 gip glucagon ly3437943 just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon receptor posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Beyond GLP-1: Retatrutide's triple-agonist mechanism

It is a double-blind, placebo-controlled study (n = 9642 T2DM patients), assessing the use of oral semaglutide once a day (up to 14 mg) during 3.55 years, evaluating the cardiovascular benefit of oral semaglutide [55]

His A1c has decreased to 5.6%

Types of GLP-1 medications GLP-1 therapies are available in several different forms: Once-weekly injections Daily oral or injectable options Combination therapy with insulins Xultophy (insulin degludec + liraglutide) IcoSema (weekly insulin Icodec + Semaglutide) Soliqua (insulin glargine and lixisenatide) How the main GLP-1 drugs compare While all GLP-1 medications work through similar mechanisms, they differ in strength, dosing frequency, weight loss effects, and side-effect profiles

GIP, glucose-dependent insulin-stimulating peptide

If someone has a history of stomach-related problems prior to taking Ozempic, this may make it harder for them to prove their case